瑞联新材发布2025年业绩快报

Core Viewpoint - The company reported a significant increase in revenue and net profit for the year 2025, indicating strong growth in its pharmaceutical and electronic materials sectors [1][2]. Financial Performance - The total revenue for the reporting period reached 1.68 billion yuan, representing a year-on-year growth of 14.95% [2]. - The net profit attributable to the parent company was 310.83 million yuan, up 23.48% compared to the previous year [2]. - The net profit excluding non-recurring gains and losses was 305.98 million yuan, reflecting a growth of 28.90% [2]. - Basic earnings per share increased to 1.80 yuan, a rise of 24.14% [2]. - The weighted average return on equity improved by 1.36 percentage points to 9.88% [2]. Asset and Equity Position - Total assets at the end of the reporting period were approximately 3.65 billion yuan, an increase of 7.33% from the beginning of the period [2]. - The equity attributable to the parent company was 3.29 billion yuan, up 8.60% [2]. - The net asset value per share increased to 18.93 yuan, a growth of 9.32% [2]. Business Segments - The revenue growth in 2025 was primarily driven by the pharmaceutical and electronic materials segments [1][3]. - In the pharmaceutical sector, the main products benefited from customer inventory adjustments and increased sales volume [1][3]. - The electronic materials segment saw growth due to successful validation of semiconductor photoresist materials and the introduction of packaging materials [1][3]. Operational Efficiency - The company focused on enhancing operational management efficiency and reducing costs through lean processes and improved management systems [3]. - Efforts were made to strengthen the coordination between research, production, supply, and sales to lower production costs and enhance profitability [3]. Product Focus - The company specializes in the research, production, and sales of specialty organic new materials, including monomer liquid crystals, OLED materials, and innovative pharmaceutical intermediates [3]. - The end applications of these products include OLED displays, TFT-LCD displays, and pharmaceutical formulations [3].